Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, Sun J, Vallon-Christersson J, Haraldsson K, Hemann MT, Borg Å, Levander F, Stegmaier K, Pietras K, Rönnstrand L, Kazi JU.
Lindblad O, et al. Among authors: kabir nn.
Oncogene. 2016 Sep 29;35(39):5119-31. doi: 10.1038/onc.2016.41. Epub 2016 Mar 21.
Oncogene. 2016.
PMID: 26999641
Free PMC article.